Latest Information Update: 12 Jul 2006
At a glance
- Originator Isis Pharmaceuticals
- Class Anti-inflammatories; Antisense oligonucleotides
- Mechanism of Action Tumour necrosis factor inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammatory bowel diseases